Ophthalmology biotech debuts with $100M Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 17 September, 2025

Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Join us.

news Lilly unwraps more Phase 3 obesity pill data, but they still lag behind Novo's oral Wegovy Roivant tees up dermatomyositis drug filing on heels of Phase 3 success GSK budgets $30B to boost US presence Ollin lands $100M to test eye drugs from Chinese partners and bring in more assets AstraZeneca's Fasenra once again falls short in COPD Sanofi claims Phase 2a success in chronic skin condition

Sep 23 11:00am ET Data you can trust: Setting the bar for ML/LLM-extracted real-world data sponsored by Flatiron Sep 25 11:00am ET Speed meets precision: Unlocking high-parameter flow cytometry with acoustic focusing sponsored by Thermo Fisher Oct 02 10:30am ET Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery sponsored by Lilly Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Biopharma is grappling with diverging policies between the US, EU, and Asia — including proposed drug pricing reforms in the US and new EU regulations taking effect this year. The need for strategic clarity has never been more urgent. Join us in London — in person and virtually — where we’re bringing together the industry’s most influential voices to chart a path forward.

ENDPOINTS PHARMA Pfizer, Novartis, BMS, Lilly and others targeted in FDA's TV ad crackdown Short-term government spending bill includes OTC drug user fees Drugmakers submit plans to join 340B rebate model pilot program Covid-19 vaccine makers sidelined ahead of upcoming ACIP meeting, sources say Watch: Which digital health tools are worth the cost?

in case you missed it 1. Genmab ends work on ADC from $1.8B acquisition of ProfoundBio 2. Dualitas gets $65M in Series A to develop bispecifics for immunology 3. Former CinCor executives return with new ‘hub-and-spoke’ company, old Sanofi drug 4. Eli Lilly picks Virginia for $5B API site as part of $27B US pledge 5. CSL commits $117M to help bring VarmX’s blood clotting drug to market 6.